Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Butterfly NetworkBFLY -0.80%54 3-Year EBITDA Growth Rate is 30.50% as of Jun. 2026, which is 35% below its 10-year median of 46.85. GuruFocus rates BFLY with a GF Score™ of 54/100 and a GF Value™ of $2.46 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Butterfly Network ranks better than 77.76% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 30.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 46.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Butterfly Network was 71.70% per year. The lowest was -19.20% per year. And the median was 46.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Butterfly Network 3-Year EBITDA Growth Rate Related Terms
BFLY vs UFPT, ALMR, ESTA: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Butterfly Network's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Butterfly Network 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Butterfly Network's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Butterfly Network's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 30.50% mean?
Butterfly Network (BFLY) has a 3-Year EBITDA Growth Rate of 30.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Butterfly Network and its competitors. This is 35% below median its historical median of 46.85. According to the industry distribution chart, Butterfly Network ranks #153 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 22.2%.
Is Butterfly Network's 3-Year EBITDA Growth Rate too high?
Butterfly Network's current 3-Year EBITDA Growth Rate of 30.50% is 35% below median its 10-year median of 46.85. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Butterfly Network's value of 30.50% is 286.1% above this industry median. Based on the distribution chart, Butterfly Network ranks #153 out of 688 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Butterfly Network has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Butterfly Network's 3-Year EBITDA Growth Rate compare to UFPT and ALMR?
According to the Medical Devices & Instruments industry distribution chart, Butterfly Network ranks #153 out of 688 companies for 3-Year EBITDA Growth Rate. This places Butterfly Network in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.90. Butterfly Network's value of 30.50% is 286.1% above this benchmark. While the company's 10-year median is 46.85 vs. the industry median of 7.90, Butterfly Network has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Butterfly Network's current 3-Year EBITDA Growth Rate of 30.50% is 286.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Butterfly Network and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Butterfly Network's current 3-Year EBITDA Growth Rate is 30.50%, which is 35% below median its own 10-year median of 46.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Butterfly Network stock overvalued right now?
Based on GuruFocus' analysis, Butterfly Network (BFLY) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.46, compared to a current price of $7.46 — trading 203.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 30.50%, which is 35% below median its 10-year median of 46.85 and 286.1% above the Medical Devices & Instruments industry median of 7.90. Butterfly Network's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Butterfly Network (BFLY), the current 3-Year EBITDA Growth Rate is 30.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Butterfly Network (BFLY) Overvalued in 2026?
Based on GuruFocus' analysis, Butterfly Network stock appears to be overvalued.
The current stock price of $7.46 is trading 203.3% above its estimated GF Value™ of $2.46.
GuruFocus considers Butterfly Network to be Significantly Overvalued.
Key valuation signals for BFLY:
3-Year EBITDA Growth Rate: 30.50% (35% below median its 10-year median of 46.85)
GF Value™: $2.46 vs. price of $7.46 (203.3% above fair value)
Industry Position: 286.1% above the Medical Devices & Instruments median (#153 of 688)
No single metric tells the full story. See the BFLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
54GF Score
Get the complete analysis for BFLY
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BFLY has been successfully added to your 
